Antagonistic human FcyRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo

Antagonistic human FcyRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo

Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and patients display intrinsic or acquired resistance. Here, we demonstrate the therapeutic potential of targeting human (h) Fc?RIIB (CD32B), a rece...

Full description

Bibliographic Details
Main Authors: Roghanian, Ali (Author), Teige, Ingrid (Author), Mårtensson, Linda (Author), Cox, Kerry L. (Author), Kovacek, Mathilda (Author), Ljungars, Anne (Author), Mattson, Jenny (Author), Sundberg, Annika (Author), Vaughan, Andrew T. (Author), Shah, Vallari (Author), Smyth, Neil R. (Author), Sheth, Bhavwanti (Author), Chan, H.T. Claude (Author), Li, Zhan-Chun (Author), Williams, Emily L. (Author), Manfredi, Giusi (Author), Oldham, Robert J. (Author), Mockridge, C. Ian (Author), James, Sonya A. (Author), Dahal, Lekh N. (Author), Hussain, Khiyam (Author), Nilsson, Björn (Author), Verbeek, J. Sjef (Author), Juliusson, Gunnar (Author), Hansson, Markus (Author), Jerkeman, Mats (Author), Johnson, Peter W.M (Author), Davies, Andrew (Author), Beers, Stephen A. (Author), Glennie, Martin J. (Author), Frendéus, Björn (Author), Cragg, Mark S. (Author)
Format: Article
Language:English
Published: 2015-04-13.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items